Real-World data on ripretinib for advanced GIST: what does it mean for patients?
NCT ID NCT06619275
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study in Germany followed 10 patients with advanced gastrointestinal stromal tumor (GIST) who had already tried three or more prior treatments. Researchers tracked how ripretinib affected their quality of life and disease control in everyday clinical practice. The goal was to gather real-world information on the drug's benefits and safety outside of a controlled trial setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ripretinib (a kinase inhibitor drug)
- What this could lead to
- If successful, this study could provide real-world evidence on how ripretinib affects quality of life and disease control in advanced GIST patients.
- What could go wrong
- This is a small observational study (10 participants) with no control group, so results may not apply broadly. It does not test a new treatment, only observes routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Praxis für interdisziplinäre Onkologie und Hämatologie
Freiburg im Breisgau, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive GIST registry aims to unlock secrets of rare cancer
- New Two-Tooth clip aims to make stomach tumor removal safer and faster
- New drug combo shows promise for Hard-to-Treat stomach cancer
- New hope for GIST: experimental combo targets hard-to-treat tumors
- New hope for advanced GIST: experimental drug NB003 takes on resistant tumors
- Scientists launch massive GIST registry to unlock secrets of rare cancer